Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Fuji
McKesson
Chubb
Argus Health
Cantor Fitzgerald
US Department of Justice
Cipla
Express Scripts

Generated: August 20, 2018

DrugPatentWatch Database Preview

Valeant Company Profile

« Back to Dashboard

Summary for Valeant
International Patents:269
US Patents:40
Tradenames:102
Ingredients:80
NDAs:125
Patent Litigation for Valeant: See patent lawsuits for Valeant

Drugs and US Patents for Valeant

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Intl CARDIZEM diltiazem hydrochloride TABLET;ORAL 018602-004 Dec 8, 1986 AB RX Yes Yes ➤ Sign Up ➤ Sign Up
Valeant Pharm Intl ELDECORT hydrocortisone CREAM;TOPICAL 080459-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Valeant Pharms North APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-002 Apr 23, 2008 RX Yes No 7,662,407 ➤ Sign Up Y ➤ Sign Up
Valeant Pharms North VENLAFAXINE HYDROCHLORIDE venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 090071-003 Apr 15, 2011 AB RX No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Valeant

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Intl CARDIZEM CD diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020062-001 Aug 10, 1992 5,470,584 ➤ Sign Up
Valeant Pharms Llc TASMAR tolcapone TABLET;ORAL 020697-002 Jan 29, 1998 5,236,952 ➤ Sign Up
Valeant Intl CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-006 Feb 6, 2003 5,288,505 ➤ Sign Up
Valeant Pharms North RETIN-A tretinoin CREAM;TOPICAL 017340-001 Approved Prior to Jan 1, 1982 3,906,108 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for VALEANT drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Rectal Gel 5 mg/mL, 4mL pre-filled syringe ➤ Subscribe 2008-12-08
➤ Subscribe Gel 0.1% ➤ Subscribe 2010-07-08
➤ Subscribe Extended-release Tablets 174 mg ➤ Subscribe 2009-09-28
➤ Subscribe Extended-release Tablets 120 mg, 180 mg, 240 mg, 300 mg and 360 mg ➤ Subscribe 2005-08-30
➤ Subscribe Extended-release Tablets 522 mg ➤ Subscribe 2009-12-24
➤ Subscribe Extended-release Tablets 150 mg and 300 mg ➤ Subscribe 2004-09-21
➤ Subscribe For Inhalation Solution 6 gm/vial ➤ Subscribe 2014-05-22
➤ Subscribe Extended-release Tablets 200 mg ➤ Subscribe 2007-03-28
➤ Subscribe Extended-release Tablets 9 mg ➤ Subscribe 2013-03-11
➤ Subscribe Tablets 1.1 g ➤ Subscribe 2013-11-05
➤ Subscribe Rectal Gel 2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL, 15 mg/3 mL and 20 mg/4 mL ➤ Subscribe 2004-03-23
➤ Subscribe Rectal Gel 5 mg/mL, 2mL pre-filled syringe ➤ Subscribe 2008-12-23
➤ Subscribe Gel 0.04% ➤ Subscribe 2010-12-20
➤ Subscribe Extended-release Tablets 348 mg ➤ Subscribe 2009-09-24
➤ Subscribe Extended-release Tablets 420 mg ➤ Subscribe 2005-04-25
➤ Subscribe Capsules 75 mg ➤ Subscribe 2011-06-06
➤ Subscribe Extended-release Tablets 100 mg ➤ Subscribe 2007-01-08
➤ Subscribe Extended-release Tablets 300 mg ➤ Subscribe 2007-09-25
➤ Subscribe Extended-release Capsules 0.375 g ➤ Subscribe 2012-04-03
➤ Subscribe Cream 0.5% ➤ Subscribe 2011-07-29
Premature patent expirations for VALEANT

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Sign Up ➤ Sign Up

Non-Orange Book US Patents for Valeant

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,932,628 Modified release formulations of a bupropion salt ➤ Sign Up
9,592,203 Controlled release and taste masking oral pharmaceutical composition ➤ Sign Up
7,645,901 Modified release formulations of a bupropion salt ➤ Sign Up
7,884,136 Modified-release formulations of a bupropion salt ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Valeant Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0918 Netherlands ➤ Sign Up PRODUCT NAME: NALTREXON OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER NALTREXONHYDROCHLORIDE, EN BUPROPION OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER BUPROPIONHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/14/988 20150330
/2000 Austria ➤ Sign Up PRODUCT NAME: BUPROPION HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-23680 20000616; FIRST REGISTRATION: NL 24160 19991201
90049-3 Sweden ➤ Sign Up PRODUCT NAME: KLINDAMYCIN (SOM KLINDAMYCINFOSFAT) OCH TRETINOIN; NAT. REG. NO/DATE: MTNR 46193 20130503; FIRST REG.: IR PA1332/043/001 20130322
C0013 Belgium ➤ Sign Up PRODUCT NAME: TIMOLOLI MALEAS EQ. TIMOLOLUM; NATIONAL REGISTRATION/DATE: 922 IS 166 F 13 19950627; FIRST REGISTRATION: SE 11901 19930910
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
QuintilesIMS
McKinsey
Accenture
Queensland Health
Fish and Richardson
UBS
Julphar
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.